Rakovina Therapeutics (FRA:7JO0) Tariff Resilience Score: 5/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7JO0 Rakovina Therapeutics Inc FRA:7JO0
27 GF Score
Price €0.07
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Tariff Resilience Score?

Rakovina Therapeutics FRA:7JO0 -13.26% 27 Tariff Resilience Score is 5 as of Jul. 14, 2026. GuruFocus rates FRA:7JO0 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,370 Biotechnology companies, Rakovina Therapeutics ranks better than 62.41% on this metric.

Rakovina Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Rakovina Therapeutics has Rakovina Therapeutics is in the biotech sector, with potential exposure to tariffs on imported research materials. The company is in early stages, limiting current impact, but future commercialization could face tariff challenges. Mitigation includes local partnerships.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Rakovina Therapeutics might have Average Resilient.

Rakovina Therapeutics  (FRA:7JO0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Rakovina Therapeutics Tariff Resilience Score Related Terms

FRA:7JO0 vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Rakovina Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Tariff Resilience Score falls into.


FRA:7JO0
27GF Score
Rakovina Therapeutics Inc FRA:7JO0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Rakovina Therapeutics (FRA:7JO0) has a Tariff Resilience Score of 5 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Rakovina Therapeutics ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Rakovina Therapeutics' Tariff Resilience Score too high?
Rakovina Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Rakovina Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Rakovina Therapeutics ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rakovina Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rakovina Therapeutics ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Rakovina Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Rakovina Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rakovina Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rakovina Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (FRA:7JO0) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Rakovina Therapeutics' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Rakovina Therapeutics (FRA:7JO0), the current Tariff Resilience Score is 5 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
27GF Score

Get the complete analysis for FRA:7JO0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price